ArticleBlood2019
How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide.
Article in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Histocompatibility assessment in hematopoietic stem cell transplantation: recommendations from the Italian Society for Immunogenetics and Transplantation Biology (Associazione Italiana di Immunogenetica e Biologia dei Trapianti - AIBT).Blood transfusion = Trasfusione del sangue · 2024Guideline
- Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis.Stem cell research & therapy · 2020Pooled it
- Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation.Bone marrow transplantation · 2021Trial
- Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Cytokine Release Syndrome after Haploidentical Transplantation is Associated with Improved Survival Without Increasing Transplant-Related Mortality.Mediterranean journal of hematology and infectious diseases · 2026Article
- Haploidentical versus matched unrelated donor hematopoietic cell transplantation for adult patients with refractory/relapsed acute lymphoblastic leukemia: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Bone marrow transplantation · 2025Article
- Impact of post-transplant cyclophosphamide with bendamustine on immune reconstitution in young patients undergoing T-cell replete haploidentical bone marrow transplantation: results from a phase Ia/Ib clinical trial.Frontiers in immunology · 2025Article
- Haploidentical hematopoietic stem cell transplantation using post-transplant cyclophosphamide in patients with inborn errors of immunity: Experience in a reference center in ColombiaBiomedica : revista del Instituto Nacional de Salud · 2024Observational
- CAST Regimen for GvHD Prophylaxis: A CIBMTR Propensity Score-Matched Analysis.Transplantation and cellular therapy · 2024Article
- [Survival after hematopoietic stem cell transplantation with identical and haploidentical donors].Revista medica del Instituto Mexicano del Seguro Social · 2024Observational
- Expanding donor options: haploidentical transplant recipients are also highly likely to have a 7/8-matched unrelated donor.Blood advances · 2024Article
- Relapse after allogeneic transplantation with post-transplant cyclophosphamide: Shattering myths and evolving insight.Blood reviews · 2023Review
- Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS.American journal of hematology · 2023Article
- The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation.International journal of molecular sciences · 2023Article
- Hematopoietic stem cell transplantation for inborn errors of immunity: 30-year single-center experience.Frontiers in immunology · 2023Article
- In 2022, which is preferred: haploidentical or cord transplant?Hematology. American Society of Hematology. Education Program · 2022Article
- Revisiting a single day salvage conditioning following graft failure.Bone marrow transplantation · 2022Article
- Comparable survival outcomes with haploidentical stem cell transplantation and unrelated bone marrow transplantation.Bone marrow transplantation · 2022Article
- Comparable survival outcomes with haploidentical stem cell transplantation and cord blood transplantation.Bone marrow transplantation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
HLA-haploidentical hematopoietic stem cell transplantation is now one of the most commonly employed alternative donor techniques, with most centers applying T-cell-replete strategies such as that developed by the Baltimore group using high-dose posttransplant cyclophosphamide. HLA-haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide is associated with low rates of severe graft-versus-host disease and nonrelapse mortality and does not require graft manipulation or storage, which results in a low graft acquisition cost. Its remarkable safety when used with reduced-intensity conditioning has been demonstrated in patients up to 75 years old with outcomes similar to those of patients in their 50s. Several large, registry-based retrospective studies have confirmed the efficacy of HLA-haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide, achieving results comparable to those of HLA-matched hematopoietic stem cell transplantation. In this article, we describe our approach to this rapidly available and clinically simple platform and address some of the key clinical questions associated with its use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.